Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Short term Debt (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Short term Debt for 2 consecutive years, with $152000.0 as the latest value for Q3 2025.

  • Quarterly Short term Debt fell 92.01% to $152000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $152000.0 through Sep 2025, down 92.01% year-over-year, with the annual reading at $320000.0 for FY2024, N/A changed from the prior year.
  • Short term Debt for Q3 2025 was $152000.0 at NRX Pharmaceuticals, down from $16.3 million in the prior quarter.
  • The five-year high for Short term Debt was $16.3 million in Q2 2025, with the low at $26000.0 in Q1 2024.